Literature DB >> 11602785

Genetic and functional analysis of the human immunodeficiency virus (HIV) type 1-inhibiting F12-HIVnef allele.

Paola D'Aloja1,2, Anna Claudia Santarcangelo2, Stefan Arold3, Andreas Baur1, Maurizio Federico2.   

Abstract

The primary human immunodeficiency virus type 1 (HIV-1) Nef mutant F12-HIVNef is characterized by three rare amino acid substitutions, G(140)E, V(153)L and E(177)G. It was reported previously that the expression of F12-HIVNef in the context of the highly productive NL4-3 HIV-1 strain blocks virus replication at the level of virus assembly and/or release by a mechanism depending on the presence of the CD4 intracytoplasmic tail. Here, it is reported that NL4-3 HIV-1 strains expressing F12-HIVnef alleles that were back-mutated in each amino acid substitution readily replicated in CD4(+) cells. Attempting to correlate possible functional alterations with antiviral effects, both F12-HIVNef and its back mutants were tested in terms of well-characterized markers of Nef expression. Both F12-HIVNef and its G(177)E back mutant did not down-regulate CD4 as the consequence of a greatly reduced rate of CD4 internalization. On the other hand, F12-HIVNef as well as the E(140)G and L(153)V back mutants failed to activate the p62 Nef-associated kinase (p62NAK). Thus, only F12-HIVNef was defective in both accelerated rates of CD4 internalization and p62NAK activation, whereas at least one Nef function was restored in all of the back mutants. Infection of cells expressing Nef-resistant CD4 molecules with HIV-1 strains encoding F12-HIVNef back mutants showed that both the lack of accelerated CD4 endocytosis and an, as yet, still unidentified function are required for the F12-HIVNef inhibitory phenotype. These results provide a detailed functional analysis of the F12-HIVnef allele and support the idea that both CD4 accelerated internalization and p62NAK activation are part of the essential steps in the virus replication cycle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602785     DOI: 10.1099/0022-1317-82-11-2735

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.

Authors:  Linden A Green; Ying Liu; Johnny J He
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

2.  Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9.

Authors:  Claudia Muratori; Antonella Sistigu; Eliana Ruggiero; Mario Falchi; Ilaria Bacigalupo; Clelia Palladino; Elena Toschi; Maurizio Federico
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

3.  DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors.

Authors:  Flavia Ferrantelli; Francesco Manfredi; Chiara Chiozzini; Simona Anticoli; Eleonora Olivetta; Claudia Arenaccio; Maurizio Federico
Journal:  Mol Biotechnol       Date:  2018-11       Impact factor: 2.695

4.  Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1.

Authors:  Claudia Arenaccio; Chiara Chiozzini; Sandra Columba-Cabezas; Francesco Manfredi; Maurizio Federico
Journal:  Retrovirology       Date:  2014-06-12       Impact factor: 4.602

5.  The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells.

Authors:  Flavia Ferrantelli; Claudia Arenaccio; Francesco Manfredi; Eleonora Olivetta; Chiara Chiozzini; Patrizia Leone; Zulema Percario; Alessandro Ascione; Michela Flego; Paola Di Bonito; Luisa Accardi; Maurizio Federico
Journal:  Int J Nanomedicine       Date:  2019-11-07

6.  The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles.

Authors:  Chiara Chiozzini; Francesco Manfredi; Flavia Ferrantelli; Patrizia Leone; Andrea Giovannelli; Eleonora Olivetta; Maurizio Federico
Journal:  Vaccines (Basel)       Date:  2021-04-12

7.  HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response.

Authors:  Paola Di Bonito; Barbara Ridolfi; Sandra Columba-Cabezas; Andrea Giovannelli; Chiara Chiozzini; Francesco Manfredi; Simona Anticoli; Claudia Arenaccio; Maurizio Federico
Journal:  Viruses       Date:  2015-03-09       Impact factor: 5.048

Review 8.  Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes.

Authors:  Paola Di Bonito; Luisa Accardi; Luisa Galati; Flavia Ferrantelli; Maurizio Federico
Journal:  Cancers (Basel)       Date:  2019-01-24       Impact factor: 6.639

Review 9.  Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting.

Authors:  Maria Luisa Fiani; Valeria Barreca; Massimo Sargiacomo; Flavia Ferrantelli; Francesco Manfredi; Maurizio Federico
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

10.  Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs.

Authors:  Flavia Ferrantelli; Chiara Chiozzini; Francesco Manfredi; Andrea Giovannelli; Patrizia Leone; Maurizio Federico
Journal:  Vaccines (Basel)       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.